LM103 (tumor-infiltrating lymphocytes) as adjuvant treatment after surgery for non-small cell lung cancer

A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations

This trial will test whether giving LM103 (TILs) after surgery and prior PD‑1 antibody therapy helps people with resectable non‑small cell lung cancer stay cancer‑free longer.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: Suzhou BlueHorse Therapeutics Co., Ltd. (Industry-sponsored)
• Drugs / interventions: immunotherapy
• Locations: 5 sites (Guangzhou, Guangdong and 4 other locations)
• Trial ID: NCT07444437 on ClinicalTrials.gov

What this trial studies

This randomized Phase IIa trial will enroll 36 to 45 patients who received neoadjuvant PD‑1 antibody therapy and underwent complete resection for resectable non‑small cell lung cancer. Participants will be randomly assigned 1:1:1 to two different LM103 (TILs) experimental groups or a control group and followed for 24 to 36 months. Key eligibility includes age 18–75, ECOG 0–1, negative actionable driver mutations, no post‑surgery recurrence, and adequate organ function. The primary approach is to deliver LM103 as adjuvant cellular immunotherapy in the post‑operative setting to see if it reduces recurrence risk compared with control.

Who should consider this trial

Good fit: Adults 18–75 with resectable non‑small cell lung cancer who received neoadjuvant PD‑1 antibody therapy, have no post‑surgery recurrence, are driver‑mutation negative, have ECOG 0–1 and adequate organ function are the intended candidates.

Not a fit: Patients with actionable driver mutations, those with recurrent or metastatic disease after surgery, poor performance status (ECOG >1), or inadequate organ function are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, LM103 could lower the risk of cancer recurrence after surgery and improve disease‑free survival for these patients.

How similar studies have performed: TIL therapy has shown clear benefit in melanoma and promise in other cancers, but adjuvant TIL use in resected NSCLC remains experimental with limited prior data.

Eligibility criteria

Inclusion Criteria:

* At the date of signing Informed Consent Form (ICF), 18 \~75 years old, male or female;
* Expected survival time \>3 months;
* ECOG performance status 0-1;
* Pathologically diagnosed as resectable non-small cell lung cancer:

  1. Received preoperative neoadjuvant therapy (including PD-1 antibody);
  2. Screening criteria:

  i. Driver gene mutations was negative; ii. No disease recurrence (including local recurrence) after surgery; iii. Expected to complete standard adjuvant therapy.
* Patients have lesions that can be used for surgical resection or biopsy puncture;
* Patients have sufficient hematology and organ functions;
* Voluntarily sign a written informed consent form (ICF).

Exclusion Criteria:

* A history of other malignant tumors within the past 5 years, excluding malignant tumors that can be expected to heal after treatment (including but not limited to well-treated thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer, or ductal carcinoma in situ of the breast treated by radical surgery);
* Adverse reactions caused by previous treatments have not been recovered to grade ≤1 (CTCAE V6.0) (excluding alopecia and neurotoxicity, and hypothyroidism, adrenal insufficiency and hypopituitarism that cannot be restored to grade 2 as determined by the investigators for a long time);
* Any immune-related adverse reaction (irAE) with a severity level greater than grade 3 that has occurred during any previous immunotherapy and has been permanently discontinued;
* Have received vaccination within two months prior to signing the ICF, or plan to receive vaccination during the study;
* Have received TIL cell therapy, allogeneic T cell therapy or NK cell therapy within 6 months prior to signing the ICF;
* Have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation in the past;
* Suffering from or suspected of having an active autoimmune disease;
* Suffering from a large amount of pleural effusion or ascites with clinical symptoms or requiring symptomatic treatment;
* Patients with current or previous irreversible interstitial lung disease;
* Suffering from serious cardiovascular and cerebrovascular diseases;
* Suffering from an active infection that requires systemic treatment;
* Suffering from infectious diseases such as hepatitis B, hepatitis C, syphilis, AIDS;
* Patients with esophageal or gastric varices requiring immediate intervention (such as ligation or sclerotherapy), or those with a higher risk of bleeding as recommended by the investigator or gastroenterologist or hepatologist, evidence of portal hypertension (including splenomegaly found in imaging examinations), or a history of variceal bleeding must undergo endoscopic assessment within 3 months before enrollment;
* Uncontrolled metabolic disorders, such as diabetes, or other non-malignant organ or systemic diseases or secondary reactions to cancer, can lead to higher medical risks and/or uncertainties in survival assessment;
* Those who are known to be allergic to any component of the investigational drug and the LM103 product formula;
* Women who are pregnant or breastfeeding;
* As determined by the investigators, there are other severe, acute or chronic medical diseases, mental disorders or laboratory abnormalities that may increase the risks related to participation in the study or may interfere with the interpretation of the study results.

Where this trial is running

Guangzhou, Guangdong and 4 other locations

• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
• Guangdong Provincial People's Hospital — Guangzhou, Guangdong, China (Recruiting)
• Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (Not_yet_recruiting)
• Henan Provincial People's Hospital — Zhengzhou, Henan, China (Recruiting)
• The Third People's Hospital of Chengdu — Chengdu, Sichuan, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Yilong Wu, Prof. Dr. Med

Conditions Non-Small Cell Lung Cancer